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Background: Human rhinoviruses (HRVs) belong to the Picornaviridae family with high similarity to human
enteroviruses (HEVs). Limited data is available from Latin America regarding the clinical presentation and strains of
these viruses in respiratory disease.
Methods: We collected nasopharyngeal swabs at clinics located in eight Latin American countries from 3,375
subjects aged 25 years or younger who presented with influenza-like illness.
Results: Our subjects had a median age of 3 years and a 1.2:1.0 male:female ratio. HRV was identified in 16% and
HEV was identified in 3%. HRVs accounted for a higher frequency of isolates in those of younger age, in particular
children < 1 years old. HRV-C accounted for 38% of all HRVs detected. Phylogenetic analysis revealed a high
proportion of recombinant strains between HRV-A/HRV-C and between HEV-A/HEV-B. In addition, both EV-D68 and
EV-A71 were identified.
Conclusions: In Latin America as in other regions, HRVs and HEVs account for a substantial proportion of
respiratory viruses identified in young people with ILI, a finding that provides additional support for the
development of pharmaceuticals and vaccines targeting these pathogens.Background
Acute respiratory infections (ARIs) are a leading cause of
acute illness worldwide and remain the most important
cause of pediatric mortality [1]. Lower respiratory tract
infections (LRTIs) are among the leading causes of
hospitalization and death in children less than 5 years old
worldwide, particularly in resource-poor countries [2].
Human rhinoviruses (HRVs) and enteroviruses (HEVs)
belong to the Picornaviridae family and are prominent
causes of respiratory disease [3]. They share identical
genomic organization and high sequence homology [4].
Their genome is divided into three sections: a 5’untrans-
lated region (5’UTR), an open reading frame of the
polyprotein that codes for all four capsid proteins (VP1-4)
and the non-structural genes, and a 3’untranslated region [5].* Correspondence: jgarcian66@yahoo.com
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reproduction in any medium, provided the orAlthough many reports link HRV primarily to illness
in children [6,7], disease in other populations such as
military recruits [8] and nursing home residents have
been reported [9]. HRV infection often results in mild
upper respiratory disease like the common cold, but it
may also cause more serious disease by exacerbating
asthma or other pre-existing respiratory disorders. In
contrast, HEVs infect primarily the gastrointestinal tract
and can spread to other sites, but some HEVs display
specific tropism for the respiratory tract [10,11].
There are more than 100 different serotypes of HRVs
taxonomically grouped into two species HRV-A and
HRV-B, according to the alignment of nucleotide frag-
ments of the VP1 gene, the VP4/VP2 gene, and, more
recently, the whole genome sequence [4,12]. A different
species, HRV-C, that shares 53 - 57% homology at the
amino acid level with HRV-A and HRV-B, was identified
in 2006 in patients with acute LRTIs in Africa, Asia,
Australia, Europe and North America [13-16]. Since itstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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respiratory pathogen in children, causing up to 5% of
LRTIs [17] and found in 42% of children with influenza-
like infection (ILI) without identification of another
pathogen by conventional means [18]. HRV-C has also
been implicated as a frequent cause of asthma exacer-
bation in children [15]. Recent studies indicate that
HRVs, as well as HEVs, show great genetic diversity by
recombination [17,19], as has been increasingly repor-
ted for the HRV-A/HRV-C recombinants [20].
There are few reports about HRVs and HEVs as causes
of respiratory disease in Latin America [21-25], inclu-
ding one that describes HRV antibodies in Amazon
tribes [26], but no large-scale genetic characterization of
HRVs and HEVs has been performed in the region to
date. In this study, we investigated the recent circulation
of HRV and HEV with emphasis on recombinant strains
in children and young adults in Latin America.
Results
HRV and HEV in Central and South America
We collected 3,375 nasopharyngeal swabs from subjects
with ILI symptoms from eight countries throughout
Central and South America. We performed direct RT-
PCR for HRVs and HEVs and sequenced all positive
samples (n = 632) (Figure 1). Our subjects had a median
age of 3 years, ranging from less than 1 month to
25 years, an interquartile range of 1 to 8 years, and a
male/female ratio of 1.2:1.
Overall, HRVs and HEVs were identified in 16% (548
samples) and 3% (84 samples) of the ILI cases, respec-
tively. Among the HRVs, HRV-A was the most repre-
sented species (9% of ILI cases), followed by HRV-C
(6%) and HRV-B (1%). Although the number of ILI
samples collected among countries varied considerably
(Figure 2, lower panel) we found no statiscally signifi-
cant geographic differences in the proportions of HEV,
HRV-A, HRV-B, and HRV-C.
HRVs were identified significantly more frequently in
children younger than 1 year (24%) compared to those
between 1 and 5 years of age (15%) or older than five
years (13%) (Figure 2, upper panel), a statistically sig-
nificant finding (p <0.05 for both). However, using the
two proportion z-test, we noted no difference in propor-
tions of specific HRV species or HEVs per total ILI cases
among different age groups. Nevertheless, the risk of
detecting HRV-C in children younger than 5 years with
ILI was 1.59 (C.I. 1.17-2.17; p <0.05) compared to older
children and young adults (5–25 years).
Certain pre-existing respiratory conditions, such as
rhinitis or chronic bronchitis, were found more often in
those with HRV isolated (O.R. = 1.14 [95% C.I. 1.09 –
1.81]; ×2 = 7.82; p-value < 0.05). Furthermore, the presence
of these pre-existing conditions specifically increased therisk for detection of HRV-C (O.R. = 1.71 [95% C.I. 1.18 –
2.45]; ×2 = 9.17; p < 0.05); asthma was a condition that
doubled the risk of HRV-C detection (O.R. = 2.07 [95%
C.I. 1.08 – 3.79]; ×2 = 6.19; p <0.05).
Coxsackieviruses comprised the majority of the HEV
group (65% of the HEVs identified), showing a variety of
types: 9 for coxsackievirus A and 5 for coxsackievirus B
(Figure 3). In addition, we detected multiple HEV sero-
types, including EV-D68, EV-C99, EV-C104, EV-C109,
and EV-B110. We also identified EV-A71 in two par-
ticipants, both from the department of Tumbes, Peru,
although from different cities. The first subject, a one
year-old girl from the city of Tumbes (same name as the
department), presented on April 27, 2011, with fever,
rhinorrhea, cough, and erythema on pharyngeal exami-
nation. The second, a two year-old girl from the city of
Zarumilla, presented on May 10, 2011, with fever,
malaise, rhinorrhea, cough, and weight loss. Neither
subject had rash, gastrointestinal manifestations, convul-
sions, change in consciousness, or other neurological
deficits. Lastly, two polioviruses were detected and were
related to the Sabin-1 polio vaccine strain.
By cell culture/immunofluorescence (as well as real
time PCR for influenza viruses), we detected other res-
piratory viruses in 11% of the HRV-positive samples and
11% of the HEV-positive samples. The most commonly
detected viruses were adenovirus, influenza virus A and
parainfluenza virus 1 (Figure 4).
Clinical manifestations of HRV and HEV infections
Although we found a higher frequency of cough, rhi-
norrhea, and dyspnea in subjects with HRV-C compared
to those with etiologies other than HRV and HEV, this
finding was not significantly more common when com-
paring HRV-C with HRV-A or HRV-B. HEV showed a
significantly lower frequency of cough than HRV-C and
the non-HRV/non-HEV group. Finally, there was no sta-
tistically significant difference in the rate of hospitalization
for HRV-C (20%) compared to all other viruses. Other
frequencies and comparisons are on Table 1.
Temporal distribution of HRV and HEV
We analyzed the temporal distribution of the three HRV
species and HEV across six regions, grouped by similar
climatic and geographical characteristics. Figure 1 shows
the collection sites that were selected and grouped into
regions for this analysis. Figure 5 depicts the percentage
of each HRV species and HEV per total ILI samples
collected and shows that HRV was present in tropical
regions (Central America, northern and tropical forest
regions) all year long. In no region was HRV or HEV
activity detected more often in the rainy season
or the higher temperature season. However, HRV-C
accounted for a higher percentage (in most cases > 5%)
Figure 1 Sample collection sites grouped by climatic/geographic similarities. Most of the sample-collection sites (dots) throughout Latin
America were grouped into six regions (colors) by their climatic and geographic similarities: latitude, longitude, altitude (meters above sea level),
rainy season, and the Köppen climate classification were considered. Lima, Peru, was not considered for the temporal distribution analysis
because it could not be grouped in to one of the six regions.
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the months of September 2010 to January 2011 and
dropped in the following months, while the opposite was
seen for the sites south of the equator (last four panels)
where the detection of HRV-C increased during the
months of April 2011 to July 2011.
Phylogenetic analyses of HRV and HEV in Latin America
For the 632 HRV and HEV sequences from Latin America,
separate phylogenetic trees were inferred for two regions:the 5’UTR and the VP4/VP2 protein-coding region
(Figure 6). A lack of detectable spatial patterns in the
data is shown for the VP4/VP2 coding region (upper left
tree), with all viruses detected in all countries (data not
shown).
The RDP, BOOTSCAN, and GENECONV algorithms
available in the RDP were used to identify recombinant
viruses within the coding and 5’UTR regions, separately.
No recombination events were detected within the























































Figure 2 Percentage of HRV and HEV by age and by country. The percentage of human enteroviruses (HEV) and of each human rhinovirus
species (HRV-A, HRV-B, and HRV-C) in samples from subjects with influenza like illness is shown by age (upper panel) and by country (lower panel).
The total number of samples collected for each age group and country is shown above each percentage bar (bold).
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the three methods, p < 0.05).
Recombination between the coding and 5’UTR re-
gions was identified by inferring separate phylogenies
for the coding and 5’UTR sequences and identifying
major incongruencies in tree topology.
The lower right tree depicting the 5’UTR region
shows that recombination events occur and their out-
comes are circulating in this region. HRV-C frequently
acquired the 5’UTR region of HRV-A by recombination
processes, including multiple different clades, but this
was not observed with HRV-B or any of the HEVs.
Members of the HEV-A and HEV-B clades also seemed
to undergo recombinant events at the 5’UTR region.
The HRV-C recombinant strains accounted for the
majority of HRV-C viruses detected (Table 2) as only
clade I contained the HRV-C with no recombination
events. In Figure 5, 5’UTR analysis, we have labeled four
HRV-C clades as they show different recombination
events. We show one previously published isolate that is
most representative of each clade (Table 2) [6,17,27,28]
which allowed placement of known isolates like theNAT045 isolate in clade HRV-C.II and the Antwerp
HRV 98/99 isolate in clade HRV-C.IV to better under-
stand the variability of the HRV-C strains and to com-
pare to other typing proposals [29].
Discussion
The frequency of HRV identified in our subjects with ILI
is similar or greater to what has been found for influenza
virus [30,31], human metapneumovirus [32,33], respira-
tory syncytial virus [30,31], and adenovirus [31,34] in the
region, emphasizing the potential clinical and public
health importance of this virus. Although differences in
subject recruitment strategies prevent exact comparison
between our studies and others, our HRV detection pro-
portions are similar to pediatric respiratory disease
studies from North America and Asia which had pro-
portions that varied between 7.7% and 17.4% [7,17,35].
In South America, three separate studies from Brazil ob-
served HRV detection proportions with a broader range,
15.9% to 46.7%, in children with ARI [22,23,25].
To further characterize the genetic diversity of these
viruses, we sequenced all HRVs and HEVs identified.
Figure 3 Number of human enteroviruses detected. Number of ILI samples (n = 84) in which human enteroviruses (HEVs) were detected
divided into species (A-D) and for each species divided into types (EV = enterovirus, CV = coxsackievirus, E = echovirus, and PV = poliovirus).
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the HRV viruses (58% and 38%, respectively), and showed,
in both cases, a great variety of serotypes, including more
than 60 for HRV-A. The relative low percentage of HRV-B
detected (4% of total HRVs) could relate to the fact that
this virus has been shown to present with no fever [7]
and our inclusion criteria required a fever ≥38°C, and
thus, we could have underestimated the presence of this















Figure 4 Second virus detected in HRV/HEV positive samples.
Number of ILI samples (n = 67) where a second virus was detected
in HRV-positive and HEV-positive samples.similar compositions of the three HRV species, with HRV-B
accounting for only 4-11% of all HRVs recovered from
subjects with respiratory complaints [7,17,22,35]. Among
HEVs, coxsackieviruses, both A and B, were the most pre-
dominant. We also identified low numbers of EV-D68,
which has been associated with respiratory disease by
others [10], although never in the countries of our study.
In addition, we identified two cases of EV-A71, an agent
traditionally associated with hand-foot-and-mouth disease,
as well as severe neurological and cardiac complications
[36,37]. EV-A71 has also been infrequently linked with
respiratory disease in Canada [38], Taiwan [39], and
Australia [40], although never in Latin America. While
the prior reports were associated with focal EV-A71
outbreaks, no outbreak in Peru was reported during our
study period. Nevertheless, the fact our surveillance
spanned multiple Latin American countries over a one-
year period and the only two EV-A71 cases occurred
within two weeks of each other in towns separated by a
mere 25 kilometers suggests a possible unidentified
localized outbreak. Other similarities between our
EV-A71 respiratory cases and those of prior reports
include age < 5 years and mild symptoms.
Our study shows that children younger than 1 year
had a higher proportion of HRV infection than older
children and young adults, which is consistent with
Table 1 Clinical manifestations of HRV and HEV
Patient group P value for:
Other HRV HEV
C vs. other C vs. A C vs. B C vs. HEV HEV vs. other
(n = 2810) (n = 490) (n = 75)
A B C
(n = 278) (n = 20) (n=192)
General symptoms
Malaise 2080 (74.0) 193 (69.4) 18 (90.0) 130 (67.7) 55 (73.3) 0.11 0.74 0.05 0.45 0.91
Headache 1177 (41.9) 80 (28.8) 10 (50.0) 56 (29.2) 37 (49.3) 0.06 0.96 0.19 >0.05 0.37
Muscular pain 760 (27.0) 57 (20.5) 6 (30.0) 27 (14.1) 23(30.7) 0.14 0.48 0.35 0.16 0.69
Chills 353 (12.6) 29 (10.4) 4 (20.0) 22 (11.5) 13 (17.3) 0.88 0.9 0.64 0.63 0.62
Respiratory symptoms
Cough 2558 (91.0) 260 (93.5) 20 (100.0) 183 (95.3) 61 (81.3) > 0.05 0.42 0.32 0.0006 0.009
Rhinorrhea 2260 (80.4) 238 (85.5) 18 (90.0) 168 (87.5) 56 (74.7) 0.02 0.56 0.76 0.02 0.33
Sore throat 1588 (56.5) 147 (52.9) 13 (65.0) 88 (45.8) 44 (58.7) > 0.05 0.29 0.19 0.16 0.77
Expectoration 814 (29.0) 83 (29.9) 7 (35.0) 64 (33.3) 17 (22.7) 0.47 0.66 0.93 0.4 0.57
Dyspnea 414 (14.7) 56 (20.1) 3 (15.0) 51 (26.6) 10 (13.3) 0.03 0.43 0.66 0.37 0.9
Gastrointestinal symptoms
Vomiting 718 (25.6) 61 (21.9) 4 (20.0) 48 (25.0) 18 (24.0) 0.93 0.7 0.82 0.93 0.88
Abdominal pain 472 (16.8) 35 (12.6) 4 (20.0) 27 (14.1) 18 (24.0) 0.71 0.86 0.76 0.39 0.43
Diarrhea 349 (12.4) 50 (18.0) 5 (25.0) 20 (10.4) 12 (16.0) 0.79 0.43 0.39 0.64 0.71
Nausea 289 (10.3) 30 (10.8) 0 (0.0) 22 (11.5) 8 (10.7) 0.86 0.94 —— 0.95 0.97
Hospitalization 295 (10.5) 36 (12.9) 2 (10.0) 38 (19.8) 6 (8.0) 0.09 0.42 0.73 0.49 0.84
The number of subjects presenting with each symptom is shown and the corresponding percentage is in parentheses on the right. “Other” represents ILI subjects that did not have HEVs or HRVs detected. HRV-C
has been singled out to better show the comparison to other HRV species and other viruses. P-values for single analysis of each group--Other, HRV-A, HRV-B, HRV-C and HEV--are provided in the last columns. Only











































































































































































Figure 5 Temporal distribution of HRV and HEV infections by region. The percentage of viral infections (positive samples/total collected ILI
samples per region in Figure 4) detected monthly is shown for HEV and each HRV species. The total ILI samples collected per month in each
region is represented by the continuous purple line. The rainy season (RS) is depicted by a red dotted line.









































Figure 6 Phylogenetic analyses of HRV and HEV. This illustrates that recombination events are much more prevalent in the untranslated regions
(UTRs) compared with a translated region (VP4/VP2). Separate alignments of the coding (VP4/VP2; 464 nt) and untranslated (5’UTR; 555 nt) regions’
sequences were constructed using MUSCLE v.3.8.31. Maximum likelihood phylogenetic trees were inferred separately for the non-coding and coding
regions using PhyML v.3.0 using a general-reversible substitution model with gamma-distributed among-site rate variability. Samples are labeled by
following format: “Sample code / Country of collection / Month- Year of collection.” Phylogenetic trees were colored by HRV species: HRV-A, HRV-B,
HRV-C, and four types of HEV (HEV-A, HEV-B, HEV-C and HEV-D). In addition, four HRV-C clades show different recombination events and these are
denoted individually as HRV-C.I to IV.
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had a slightly higher risk of infection by HRV-C com-
pared with those older than 5. However, no differences
in the prevalence among age groups were detected for
HEVs throughout our network.
A second virus was detected in approximately 11% of
HRV-positive samples, much lower than a rate (37%)
reported by others [23]. We used two methods of detec-
tion, PCR for influenza viruses and cell culture for allother viruses (including influenza virus), perhaps allowing
for higher identification proportions of influenza and most
likely underestimating the number of secondary infec-
tions. However, we did not observe more severe symp-
toms in patients with another respiratory virus identified,
a finding that is consistent with what has been reported
previously [23].
Several studies have suggested differences in illness
severity between HRV species, including a specific
Table 2 HRV-C clades 5’UTR phylogenetic analysis











I 29 GQ223228 China 2007 N10 Huang et al. (2009) [17]
II 24 EF077280 USA 2003 NAT045 Kistler et al. (2007) [27]
III 18 AB683895 Phillipines 2011 Fuji et al. (2011) [6]
IV 29 JN990702 USA 2009 26 Lau et al. (2007) [28]
The 5’UTR phylogenetic tree enable us to define four clades of HRV-C serotype (in Figure 6). The percentage of HRV-C samples included in each clade is shown.
For each clade, we included one previously published isolate that is most representative of each clade, which allowed placement of known isolates like the
NAT045 isolate in clade HRV-C.II and the Antwerp HRV 98/99 isolate in clade HRV-C.IV to better understand the variability of the HRV-C strains and to compare to
other typing proposals [29]. Each GenBank isolate accession number, country of collection and year of collection, strain identifier, and the reference manuscript
are shown.
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bation [6,7,35]. In agreement with these studies, our
results showed a higher frequency of dyspnea in subjects
with HRV-C compared with other viruses; in addition,
we noted an association of HRV-C detection with pre-
existing respiratory diseases, in particular with asthma.
Our phylogenetic analyses showed the presence of
almost all known serotypes of HRV-A and HRV-B, as
well as the presence of HRV-C. HRV-C variants are not
yet formally classified into types, although there have
been some proposed typing methods [29]. We show that
recombinant events occur at the 5’UTR [8] consistent
with others who reported picornaviruses having recom-
bination breakpoints restricted to non-structural regions
of their genome [42]. We showed that the circulating
HRV-C recombinants accounted for the majority of all
HRV-C species, illustrating how much this virus varies
over a very short period of time.
Limitations of our study include a lack of uniformity
in samples collected among countries and the fact that
we collected samples over a period of only one year,
preventing definitive characterization of the seasonality
of HRV and HEV in Latin America. Although an analysis
spanning three to five years would have been ideal, we
analyzed the temporal distribution of the three HRV spe-
cies and HEVs by aggregating collection sites by their
climatic and geographic similarities. As has been pre-
viously described in other continents [13,43], HRVs and
HEVs showed a similar “year-long” temporal distribution
throughout Central and South America during the one-
year period of collection. We did not detect any sea-
sonality for specific HRV-A or HRV-B species, although
HRV-C species seemed to possess opposite seasonal
trends on either side of the equator. Others have noted
seasonal differences among the individual HRV species,
including high rates of HRV-A in April in the U.S. [35]
and low rates in summer in China [41], high rates of
HRV-B during winter in Australia [40] and China [41],
and high rates of HRV-C in October in the U.S. [35] and
winter in China [17]; like ours, these studies collected
samples for only a one or two-year time span. Another
important limitation of our study was that theidentification of HRV and HEV did not unequivocally
imply causality, a factor that would have been obviated
with the inclusion of age-matched asymptomatic controls.
Although we are not the first to demonstrate a high
prevalence of HRV in children with ILI, our results pro-
vide new perspectives into this virus’s global reach and
additional insight into its clinical and phylogenetic charac-
teristics in this underreported area of the world. While
proven preventive and treatment strategies exist for other
common respiratory viruses, including respiratory syn-
cytial virus (pharmacotherapy, passive immunization),
adenovirus (active immunization), and influenza virus
(pharmacotherapy, active immunization), no HRV vaccine
or antiviral currently exists [44,45]. Our high prevalence
of HRV and HEV identification in young Latin Americans
indicates that pharmacotherapy against influenza virus or
the common bacterial etiologies of respiratory disease
should not be presumptive, but guided by diagnostic con-
firmation when available in this population. Despite the
current limitations of rapid diagnosis and clinical manage-
ment of HRV or HEV respiratory disease, we hope that
surveillance such as ours will provide further impetus for
the development of rapid diagnostic methods, vaccines,
and antivirals, as well as further elucidation of what popu-
lations are most at risk and what types of HRV and HEV
species are most worth targeting.
Methods
Ethics
This protocol was approved as less than minimal risk re-
search by the Naval Medical Research Center (NMRC),
Silver Spring, Maryland. Institutional Review Board (IRB;
Protocol NMRCD.2002.0019) in compliance with all ap-
plicable federal regulations governing the protection of
human subjects. Authorization was given to perform the
study using an information sheet approved and stamped
by the IRB. As this was part of clinical care and routine
surveillance benefiting the ministries of health, verbal con-
sent was obtained from all participants. This method of
consent was accepted by the NMRC IRB as well as by
each of the institutions involved.
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From September 2010 to September 2011, in colla-
boration with eight Central and South American coun-
tries’ ILI passive surveillance networks (Nicaragua, El
Salvador, Venezuela, Colombia, Ecuador, Peru, Paraguay
and Argentina; Figure 1), nasopharyngeal swabs were col-
lected from 3,375 subjects with ILI presenting to out-
patient medical clinics in 21 cities, as described previously
[46-49]. All participants were 25 years old or younger, had
a fever (≥38°C), and either a cough or sore throat [50].
Once collected, swabs were placed in viral transport media
and stored at −80°C until they were transported on dry ice
to the Naval Medical Research Unit No. 6 (NAMRU-6)
facilities in Lima, Peru. Every site used an identical case
report form. This form collected basic epidemiologic
information and symptoms prior to presentation.
DNA extraction and PCR
We extracted and amplified viral RNA from 140 μl of the
viral transport media using a viral RNA kit (QIAamp,
Qiagen®). This was performed in 22 μl of reaction mixture
consisting of 2.2 μl of nuclease-free water, 3 μl of MgSO4,
(5.0 ×), 15 μl of 2× reaction mix (Super Script III One-
Step RT-PCR System) with platinum (Taq High Fidelity
kit), 0.6 μl 20 μM concentrations of the sense and anti-
sense primers, 0.6 μl Enzyme Mix, and 8 μl of template.
HRV and HEV detection was performed by semi-nested
reverse transcription–PCR (RT-PCR) targeting the 5’UTR
and a partial sequence of the VP4/VP2 genes including
the nucleotides 165–1079 of the genomic RNA. We used
P1-1 HRV (CAAGCACTTCTGTYWCCCC) and 9565_R
HRV (GCATCNGGYARYTTCCACCACCAICC) [12].
The amplification was carried out in a thermocycler
7700 (Applied Bioystems, Foster City, CA). Cycling
conditions included a reverse transcription step at 50°C
for 30 min and 95°C for 15 min followed by 45 PCR
cycles: 94°C for 30 seconds; 55°C for 30 seconds; 72°C for
90 sec; and final incubation for 72°C for 10 min. The amp-
lified products of 915 bp were analyzed by electrophoresis
on an agarose 2% gel. PCR products were purified with
Centri-Seps Columns (Princeton Separations). Purified
products were directly used for sequencing of viral nucleic
acids from clinical specimens.
Sequencing and phylogenetic analyses
The 5’UTR and VP4/VP2 coding region of all HRV and
HEV positive samples obtained (n = 632) were sequenced
and included in the following phylogenetic analyses.
These regions were selected for sequencing because
VP4/VP2 is the most commonly studied region of HRV
and the 5’UTR regions have been shown to recombine
frequently. For direct sequencing of viral nucleic acids
from clinical specimens, gene fragments were amplified
and sequenced with the use of a Big Dye terminator cyclesequencing kit (version 3.1, Applied Biosystems) and in-
ternal primers Generic F HRV (AGCCTGCGTGGCK
GCC) and NCR2 HRV (ACTACTTTGGGTGTCCGTG
TTTC) on a Genetic Analyser system (version 3130xL,
Applied Biosystems).
Separate alignments of the coding (VP4/VP2; 464 nt)
and non-coding (555 nt) regions’ sequences were con-
structed using MUSCLE v.3.8.31 [51]. Maximum like-
lihood phylogenetic trees were inferred separately for
the non-coding and coding regions using PhyML v.3.0
using a general-reversible substitution model with gamma-
distributed among-site rate variability [52]. Phylogenetic
trees were visualized in FigTree v1.3.1 and colored by
HRV species: HRV-A, HRV-B, HRV-C, and four clades of
HEV (HEV-A, HEV-B, HEV-C, and HEV-D). Complete
sequences (≈1,000 nt) were assembled, aligned, and edited
using Sequencer (version 4.8 – Gene Codes Corporation,
Ann Arbor, MI, USA) and BioEdit (version 7.0.0 -Isis
Pharmaceuticals, Inc., Dublin, Ireland) software. Phyloge-
netic trees were generated with CLUSTAL X version 2.0.1
and MEGA version 3.1 software [53]. Fifty-eight HRV and
34 HEV sequences, representing all different clades found
during the analysis were submitted to GenBank and their
accession numbers are: JX129393 - JX129484. The RDP,
BOOTSCAN, and GENECONV algorithms available in
the Recombination Detection Program (RDP3, available at
http://web.cbio.uct.ac.za/~darren/rdp.html) were used to
identify recombinant viruses within the coding and 5’UTR
regions, separately.
Detection of other respiratory viruses
All HRV- and HEV-positive samples underwent viral
isolation by inoculation into four cell lines: MDCK,
Vero76, VeroE6 and LLCMK2 cells (ATCC, Manassas,
VA 20108), as previously reported [54]. After ten days of
culture, the cells were spotted onto microscope slides.
Cell suspensions were dried and fixed in chilled acetone
for 15 minutes. Immunofluorescence assay was per-
formed using the Respiratory Virus Screening and Iden-
tification Kit (D3 DFA Respiratory Virus Diagnostic
Hybrids; Athens, OH) for the identification of adeno-
viruses, influenza A and B viruses, parainfluenza viruses
(types 1, 2, 3 and 4), and respiratory syncytial virus.
In addition, real time-PCR for influenza viruses was
performed on all HRV- and HEV-positive samples as pre-
viously described [49]. This was performed as part of the
routine sample processing of the respiratory surveillance
network at NAMRU-6.
Statistical analyses
Data was entered into a database using Microsoft Access
and analyzed using Stata/SE 10.0 for Windows (StataCorp
LP, College Station, TX). Two proportion z-tests were
used to compare proportions; p-values ≤0.05 were
Garcia et al. Virology Journal 2013, 10:305 Page 11 of 12
http://www.virologyj.com/content/10/1/305considered statistically significant; 95% confidence inter-
vals (C.I.) were calculated for each odd ratio (O.R.), and
associations were assessed using Pearson’s chi-square (×2)
or Fisher’s tests.
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